Sonoma pharmaceuticals announces expansion of negative-pressure wound therapy products for use in the united states

Boulder, co / accesswire / april 9, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the expansion of its microcyn® negative-pressure wound therapy (npwt) solution products in the united states. microcyn negative-pressure wound therapy solution, an innovation in advanced wound care, is now available in convenient sizes of 250ml, 450ml, and 990ml.
SNOA Ratings Summary
SNOA Quant Ranking